Results 131 to 140 of about 51,767 (241)

Synaptic Vesicle Glycoprotein 2A Suppresses Amyloidogenesis Beyond Its Synaptic Role: A Novel Mechanism Disrupting BACE1 Binding and Altering APP Localization

Aging Cell, Volume 25, Issue 2, February 2026.
Synaptic vesicle glycoprotein 2A, the newly identified APP‐binding protein, reduces amyloid‐β plaque deposition in Alzheimer's disease by suppressing the amyloidogenic pathway through inhibition of BACE1‐APP interaction and alteration of APP endosomal‐lysosomal localization.
Xiaoling Wang, Qian Zhang, Xiaomin Zhang, Jing Liu, Jingjing Zhang, Congcong Liu, Yuting Cui, Qiao Song, Yuli Hou, Yaqi Wang, Min Cao, Peichang Wang   +11 more
wiley   +1 more source

Concurrent TTR and AL Amyloidosis: Diagnostic Challenges and Clinical Implications. [PDF]

JACC Case Rep
Wats K, Chakraborty R, Navarro-Torres M, Siegelin MD, D'Agati VD, Maurer MS.   +5 more
europepmc   +1 more source

The incidence of serious complications after selective laser trabeculoplasty

Acta Ophthalmologica, Volume 104, Issue 1, Page 106-113, February 2026.
Abstract Purpose To evaluate the incidence of serious complications after selective laser trabeculoplasty (SLT). Methods All patients who underwent SLT at the Department of Ophthalmology, Helsinki University Hospital, were eligible for the study from 1 January 2012 to 31 December 2018.
Eeva S. Ojanen, Joni A. Turunen, Mika Harju   +2 more
wiley   +1 more source

Clinical significance of t(11;14) translocation in systemic AL amyloidosis in the era of daratumumab therapy. [PDF]

Clin Exp Med
Nishimura N, Kawano Y, Yasunaga JI.
europepmc   +1 more source

Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitus

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1350-1358, February 2026.
Abstract Aims To evaluate treatment‐emergent antidrug antibodies (TE ADA) in once‐weekly basal insulin efsitora‐treated participants with type 1 and type 2 diabetes mellitus (T1DM and T2DM) from 5 phase 3 clinical trials and their potential impact on pharmacokinetics, efficacy and safety.
Yun Wang, Sihe Wang, Wei Wang, Xiaoqi Li, Jennifer Leohr, Vitoria Pires, Michelle L. Katz, Christopher J. Child, Robert J. Konrad   +8 more
wiley   +1 more source

Serum and Tissue Light-Chains as Disease Biomarkers in AL Amyloidosis. [PDF]

Int J Mol Sci
Aimo A, Ferrari Chen YF, Chianca M, Mori F, Pucci A, Castiglione V, Musetti V, Caponi L, Fabiani I, Vergaro G, Franzini M, Emdin M, Cardinale D.   +12 more
europepmc   +1 more source

Tranexamic Acid for Hyperpigmentation Disorders: A Literature Review on Efficacy and Safety in Melasma and PIH

Journal of Cosmetic Dermatology, Volume 25, Issue 2, February 2026.
ABSTRACT Background Hyperpigmentation disorders, including melasma and post‐inflammatory hyperpigmentation (PIH), are common dermatologic conditions associated with significant cosmetic and psychological burden. Tranexamic acid (TXA), an antifibrinolytic agent, has gained increasing attention due to its anti‐inflammatory and antimelanogenic properties.
Ahmed AlJabr, Aseel Muhana I. AlAnazi, Rakan Abdulkarim A. AlEtebi   +2 more
wiley   +1 more source

Myocardial deformation imaging to monitor treatment response in AL amyloidosis: is it worth the strain? [PDF]

Eur Heart J Open
Castiglione V, Gentile F, Vergaro G.
europepmc   +1 more source

Silver-positive kidney AL amyloidosis

Francesco Fontana, Gaetano Alfano, Laura Verga, Riccardo Magistroni, Gabriele Donati   +4 more
openalex   +2 more sources

Characterizing a racially diverse cohort of patients with AL amyloidosis treated with dara-VCD [PDF]

Dominique Mosley, Richa Parikh, Sara Scott, Nisha Joseph, Craig Hofmeister, Vikas Gupta, Nishi Shah, Sagar Lonial, Ajay Nooka, Jonathan Kaufman   +9 more
openalex   +1 more source